Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Magrolimab Falls Off The Fast Track As Gilead Reveals New Clinical Holds

Biktarvy Settlement Totals $1.25bn Up Front, 3% US Bictegravir Royalty

Executive Summary

The company said in its fourth quarter earnings report that it would not seek accelerated approval for the drug, while it also settled an HIV drug-related intellectual property lawsuit with GSK/ViiV.

You may also be interested in...



Gilead’s Magrolimab Mostly Back On Track As FDA Lifts AML, MDS Holds

The clinical holds, initially announced in January, raised concerns about the company losing its edge in CD47-targeting drugs. Partial holds on the DLBCL and myeloma programs remain in place.

Kite’s Yescarta Is First CAR-T To Move Into Second-Line Lymphoma

Kite beats BMS’s Breyanzi to the first CAR-T approval in second-line large B-cell lymphoma. The added indication could nearly double the number of potential US patients for Yescarta.

Trodelvy’s Phase III Breast Cancer Results Raise More Questions Than Answers

Gilead is staying mum about the TROPiCS-02 data, which is fueling speculation that the drug’s benefit may have been modest.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145812

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel